



OPEN

# Necro-inflammatory activity grading in chronic viral hepatitis with three-dimensional multifrequency MR elastography

Philippe Garteiser<sup>1✉</sup>, Gwenaél Pagé<sup>1</sup>, Gaspard d'Assignies<sup>1,2</sup>, Helena S. Leitao<sup>1,2</sup>, Valérie Vilgrain<sup>1,2</sup>, Ralph Sinkus<sup>3</sup> & Bernard E. Van Beers<sup>1,2</sup>

The purpose of this study was to assess the diagnostic value of multifrequency MR elastography for grading necro-inflammation in the liver. Fifty participants with chronic hepatitis B or C were recruited for this institutional review board-approved study. Their liver was examined with multifrequency MR elastography. The storage, shear and loss moduli, and the damping ratio were measured at 56 Hz. The multifrequency wave dispersion coefficient of the shear modulus was calculated. The measurements were compared to reference markers of necro-inflammation and fibrosis with Spearman correlations and multiple regression analysis. Diagnostic accuracy was assessed. At multiple regression analysis, necro-inflammation was the only determinant of the multifrequency dispersion coefficient, whereas fibrosis was the only determinant of the storage, loss and shear moduli. The multifrequency dispersion coefficient had the largest AUC for necro-inflammatory activity  $A \geq 2$  [0.84 (0.71–0.93)] vs. storage modulus AUC: 0.65 (0.50–0.79),  $p = 0.03$ , whereas the storage modulus had the largest AUC for fibrosis  $F \geq 2$  [AUC (95% confidence intervals) 0.91 (0.79–0.98)] and cirrhosis  $F4$  [0.97 (0.88–1.00)]. The measurement of the multifrequency dispersion coefficient at three-dimensional MR elastography has the potential to grade liver necro-inflammation in patients with chronic viral hepatitis.

## Abbreviations


ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
AUC	Area under the receiver operating characteristic curve
MR	Magnetic resonance
NASH	Nonalcoholic steatohepatitis
ROI	Region of interest
$G'$	Storage modulus
$G''$	Loss modulus
$ G^* $	Shear modulus
$\zeta$	Damping ratio
$\gamma$	Multifrequency dispersion coefficient

Ultrasound and magnetic resonance (MR) elastography are increasingly used for staging liver fibrosis in patients with hepatitis B and C<sup>1–4</sup>. Most patients with chronic viral hepatitis and liver fibrosis also have necro-inflammatory activity. Necro-inflammation has potential prognostic and therapeutic consequences<sup>5–8</sup>.

Although MR elastography accurately stages liver fibrosis, its role in grading liver necro-inflammation remains debated. Necro-inflammation may increase liver stiffness in diffuse liver diseases<sup>4,9,10</sup>, but its influence on liver stiffness is less prominent than that of fibrosis<sup>4,11,12</sup>.

With three-dimensional MR elastography the complete wave field is measured to calculate the viscoelastic properties of the liver<sup>2,13</sup>. These parameters include first, the magnitude of the complex shear modulus  $|G^*|$ , also

<sup>1</sup>Laboratory of Imaging Biomarkers, Center for Research on Inflammation, UMR 1149 Inserm, Université de Paris, 75018 Paris, France. <sup>2</sup>Department of Radiology, Beaujon University Hospital Paris Nord, AP-HP, 92110 Clichy, France. <sup>3</sup>Laboratory for Vascular Translational Science, UMR 1148 Inserm, Université de Paris, 75018 Paris, France. ✉email: philippe.garteiser@inserm.fr



**Figure 1.** study flowchart shows patients with inclusion and exclusion criteria.

Parameter	Intraclass correlation coefficient [95% confidence interval]	Bland–Altman bias (%)	Reproducibility coefficient (%)
Shear modulus, $G^*$	0.994 [0.989–0.997]	– 1.4	9.2
Storage modulus, $G'$	0.995 [0.990–0.997]	– 1.3	7.9
Loss modulus, $G''$	0.985 [0.972–0.992]	– 1.3	15.3
Damping ratio, $\zeta$	0.954 [0.918–0.974]	0.0	12.4
Multifrequency dispersion coefficient, $\gamma$	0.950 [0.721–0.983]	– 5.2	16.4

**Table 1.** Interobserver reproducibility of the biomechanical parameters.

called shear stiffness; second, the storage  $G'$  and loss  $G''$  moduli (real and imaginary parts of the complex-valued shear modulus) which reflect elasticity and viscosity respectively; and third the damping ratio  $\zeta = G''/(2 \cdot G')$  related to the viscosity to elasticity ratio<sup>14,15</sup>.

Moreover, with the advent of rapid acquisition schemes for multifrequency MR elastography, the exploration of the frequency behavior of liver disease has become clinically feasible<sup>3,16,17</sup>. The biomechanical moduli of a tissue have a frequency dependence which is best described by a power law<sup>11,18,19</sup>. The exponent of the power law or multifrequency dispersion coefficient is an indicator of tissue architecture and is influenced by the solid/liquid composition of tissue<sup>18,20,21</sup>.

These additional viscoelastic parameters at MR elastography may help assessing tissue activity. With mono-frequency data acquisition, it was shown that the damping ratio and loss modulus are useful to differentiate between simple steatosis and steatohepatitis in mice and patients<sup>15,22,23</sup>. Using multifrequency data acquisition, it was observed that the dispersion coefficient decreased in the brain of patients with chronic neuro-inflammation and in obese rat pancreas containing fibro-inflammatory complexes<sup>24,25</sup>.

The value of multifrequency MR elastography for diagnosing hepatic necro-inflammation and distinguishing it from fibrosis has not yet been assessed to the best of our knowledge. The aim of our study was to assess the diagnostic value of three-dimensional multifrequency MR elastography for necro-inflammatory activity grading in patients with chronic viral hepatitis.

## Results

**Clinical and histopathologic parameters.** Patient age ranged from 25 to 68 years [median: 47 years, 95% confidence interval: (40–52 years)] and 73% of the patients were men. Eighteen patients had chronic viral hepatitis B and 32, chronic viral hepatitis C. The data of three patients (hepatitis B:  $n = 2$ , hepatitis C:  $n = 1$ ) were excluded because of patient motion during the MR elastography examination and low wave amplitude or low wave amplitude (Fig. 1). At histopathology, the necro-inflammatory grade was A0 in 7 patients (15%), A1 in 27 patients (57.5%), A2 in 10 patients (21%) and A3 in 3 patients (6.5%). Five patients (11%) had F0 fibrosis, 19 patients (40%) F1, 9 patients (19%) F2, 9 patients (19%) F3, and 5 patients (11%) F4. Thirteen patients (28%) had substantial inflammation  $\geq A2$  and 23 patients (49%) had substantial fibrosis  $\geq F2$  (Supplementary table 1).

**Reproducibility.** Shear stiffness measurements displayed intraclass correlation coefficient of 0.994 [95% confidence interval (0.989–0.997)], interobserver reproducibility coefficient of 9.2% and bias of – 1.4%. The other biomechanical parameters displayed similar levels of reproducibility (Table 1).

**Biomechanical parameters versus activity and fibrosis.** The biomechanical parameter graphs according to the histological classification of activity and fibrosis are shown in Figs. 2 and 3 (and in detail in supplementary figs. S1 and S2) and clinical examples are illustrated in Fig. 4. Regarding necro-inflammation, only the multifrequency dispersion coefficient differed significantly between patients without and with substantial activity (A0–A1:  $1.3 \pm 0.2$  vs. A2–A3:  $1.0 \pm 0.1$ ,  $p = 0.0003$ ). The corresponding values for the storage modulus were  $2.3 \pm 0.8$  kPa versus  $2.9 \pm 1.4$  kPa,  $p = 0.11$ , for the loss modulus  $1.3 \pm 0.4$  kPa versus  $1.5 \pm 0.7$  kPa,  $p = 0.70$ , for the shear modulus  $2.8 \pm 0.9$  kPa versus  $3.4 \pm 1.6$  kPa,  $p = 0.27$ , and for the damping ratio  $0.3 \pm 0.1$  kPa versus  $0.3 \pm 0.04$  kPa,  $p = 0.19$  (Figs. 2, 3).

The multifrequency dispersion coefficient decreased with increasing necro-inflammation and fibrosis, whereas the monofrequency storage, loss and shear moduli increased significantly with increasing fibrosis and necro-inflammation scores. The storage modulus showed the highest differences between groups of increasing fibrosis (F0–F1:  $2.0 \pm 0.2$  kPa, F2:  $2.6 \pm 0.4$  kPa and F3–F4:  $3.4 \pm 1.4$  kPa, Kruskal–Wallis  $p = 0.000008$ ), versus the loss modulus (F0–F1:  $1.1 \pm 0.3$  kPa, F2:  $1.4 \pm 0.4$  kPa and F3–F4:  $1.7 \pm 0.7$  kPa, Kruskal–Wallis  $p = 0.001$ ), the shear modulus (F0–F1:  $2.4 \pm 0.3$  kPa, F2:  $3.0 \pm 0.5$  kPa and F3–F4:  $3.9 \pm 1.6$  kPa, Kruskal–Wallis  $p = 0.00002$ ), and the multifrequency dispersion coefficient (F0–F1:  $1.3 \pm 0.2$ , F2:  $1.1 \pm 0.2$  and F3–F4:  $1.1 \pm 0.2$ , Kruskal–Wallis  $p = 0.003$ ). The damping ratio did not differ between the groups with increasing fibrosis (F0–F1:  $0.3 \pm 0.1$ , F2:  $0.3 \pm 0.1$  and F3–F4:  $0.3 \pm 0.04$ , Kruskal–Wallis  $p = 0.56$ ) (Fig. 4).

**Correlations.** At univariate analysis, significant correlation was observed between the multifrequency dispersion coefficient and necro-inflammatory activity ( $r = -0.63$ ,  $p < 0.0001$ ). The only other viscoelastic parameter correlated to activity was the storage modulus, although with lower correlation coefficient ( $r = 0.34$ ) and less significance ( $p = 0.02$ ). In contrast, all viscoelastic parameters, except the damping ratio, displayed significant correlations with fibrosis (Table 2). The storage modulus showed the best correlation with fibrosis ( $r = 0.65$ ,  $p < 0.0001$ ).

The serum aminotransferase levels were correlated with the multifrequency dispersion coefficient (ALT:  $r = -0.50$ ,  $p = 0.0004$ ; AST:  $r = -0.50$ ,  $p = 0.0003$ ), and with the shear and storage moduli (ALT:  $r = 0.31$ ,  $p = 0.03$ ; AST:  $r = 0.44$ ,  $p = 0.002$  for shear modulus, and ALT:  $r = 0.43$ ,  $p = 0.0025$ ; AST:  $r = 0.51$ ,  $p = 0.0003$  for storage modulus). Moreover, there was a significant correlation ( $r = 0.54$ ,  $p < 0.0001$ ) between necro-inflammation and fibrosis.

At stepwise multivariate analysis, necro-inflammation was the only independent determinant of the multifrequency dispersion coefficient ( $r_{\text{partial}} = -0.60$ ,  $p < 0.0001$ ), whereas fibrosis was a determinant of the shear, storage and loss moduli ( $r_{\text{partial}} = 0.66$ ,  $p < 0.0001$ ,  $r_{\text{partial}} = 0.68$ ,  $p < 0.0001$ , and  $r_{\text{partial}} = 0.54$ ,  $p < 0.0001$ , respectively). The damping ratio was not affected by any of the tested parameters (Table 3).

**Diagnostic performance.** At ROC analysis, the multifrequency dispersion coefficient was the only parameter among the biomechanical and biological parameters displaying high AUC ( $\geq 0.8$ ) for any activity grade [AUC (95% confidence interval) 0.86 (0.73–0.85),  $p < 0.0001$  for  $A \geq 1$ ; 0.84 (0.71–0.93),  $p < 0.0001$  for  $A \geq 2$ ; and 0.88 (0.75–0.96),  $p < 0.0001$  for  $A = 3$ ] (supplementary table 2). The AUC of the multifrequency dispersion coefficient for substantial activity ( $A \geq 2$ ) was significantly larger than the AUC of the storage modulus (0.84 vs. 0.65,  $p = 0.03$ ) (Fig. 5).


At a threshold value of 1.2, the sensitivity and specificity of the multifrequency dispersion coefficient for substantial activity  $A \geq 2$  were 100% and 68% respectively with their positive and negative predictive values being 54% and 100% respectively. With a threshold value of 2.3 kPa, the corresponding figures for the storage modulus were 62% sensitivity, 79% specificity, 53% positive predictive value, and 84% negative predictive value (Supplementary table 2).

The storage modulus had the largest AUC for staging substantial fibrosis  $F \geq 2$  [0.91 (0.79–0.98),  $p < 0.0001$ ] (Table 4). In comparison, the multifrequency dispersion coefficient had AUC of 0.79 [0.65–0.90] ( $p < 0.0001$ ) for substantial fibrosis. The difference of AUC between the storage modulus and the multifrequency dispersion coefficient was not statistically significant ( $p = 0.18$ ) (Fig. 5). For cirrhosis ( $F = 4$ ), the storage modulus and the shear modulus had similar high AUC [0.97 (0.88–1.00),  $p < 0.0001$ ]. In contrast, the multifrequency dispersion coefficient did not have a significant AUC [0.57 (0.41–0.71),  $p = 0.65$ ].


At a threshold value of 1.2, the sensitivity and specificity of the multifrequency dispersion coefficient for substantial fibrosis  $F \geq 2$  were 83% and 71%, respectively with a positive predictive value of 73% and negative predictive value 81%. With a threshold value of 2.2 kPa, the corresponding figures for the storage modulus were as follows: 83% sensitivity, 96% specificity, 95% positive predictive value and 85% and negative predictive value (supplementary table 2).

## Discussion


In patients with chronic viral hepatitis, we have observed that the wave dispersion coefficient at multifrequency MR elastography has high diagnostic accuracy for grading necro-inflammation and we have confirmed that the monofrequency visco-elastic parameters, especially the storage and shear moduli have high diagnostic accuracy for determining fibrosis stage<sup>12,26</sup>. The model independent power law exponent used to assess wave dispersion in our work is a measurement that describes how the shear modulus varies with frequency<sup>18,27</sup>. The decrease of the multifrequency wave dispersion coefficient in hepatic necro-inflammation might be explained by an increase of edema and angiogenesis, and/or by a change of the collagen network topology<sup>11,18,20,21</sup>. Previous studies reporting on multifrequency dispersion in inflammation are sparse. Decreased power law dispersion at MR elastography has been reported in chronic neuro-inflammation and in the inflamed pancreas of obese rats<sup>24,25</sup>.



**Figure 2.** Boxplots (boxes: 1st to 3rd quartiles, whiskers: 1st quartile— $1.5 \times$  interquartile range to 3rd quartile +  $1.5 \times$  interquartile range, horizontal line: median) of multifrequency dispersion coefficient ( $\gamma$ , panel A), storage modulus ( $G'$ , panel B), loss modulus ( $G''$ , panel C), shear modulus ( $|G^*|$ , panel D) and damping ratio ( $\zeta$ , panel E) at 56 Hz in patients with increasing necro-inflammatory score. For the two necro-inflammatory activity groups, boxplots are subdivided relative to fibrosis scores. Only multifrequency dispersion coefficient differs significantly between patients without and with substantial activity ( $p=0.0003$ ).



**Figure 3.** Boxplots (boxes: 1st to 3rd quartiles, whiskers: 1st quartile—1.5  $\times$  interquartile range to 3rd quartile + 1.5  $\times$  interquartile range, horizontal line: median) of multifrequency dispersion coefficient ( $\gamma$ , panel A) and monofrequency (56 Hz) storage modulus ( $G'$ , panel B), loss modulus ( $G''$ , panel C), shear modulus ( $|G^*|$ , panel D) and damping ratio ( $\zeta$ , panel E) in patients with increasing fibrosis. For each fibrosis group, boxplots are subdivided relative to the necro-inflammatory activity. Frequency dispersion coefficient decreases significantly ( $p=0.003$ ) with increasing fibrosis score, whereas storage, loss and shear moduli increase significantly with fibrosis score ( $p=0.000008$ ,  $p=0.001$ , and  $p=0.00002$ , respectively). Damping ratio does not differ significantly between groups.




**Figure 4.** Parametric maps of storage modulus  $G'$  (A,B) and multifrequency dispersion coefficient  $\gamma$  (C,D) in patient with F2/A1 histological score (A,C) and patient with F2/A3 score (B,D). Storage modulus is similar (mean storage modulus: 2.4 kPa in (A) versus mean 2.3 kPa in (B) in the two patients with same F2 score, whereas multifrequency dispersion coefficient is lower in the second patient with A3 activity than in the first patient with A1 activity (mean multifrequency dispersion coefficient: 1.46 in (D) versus 0.99 in (C)).

Parameter	Fibrosis	Necro-inflammatory activity	ALT*	AST*
Storage modulus ( $G'$ )	0.65 ( $p < 0.0001$ )	0.34 ( $p = 0.203$ )	0.43 ( $p = 0.0025$ )	0.51 ( $p = 0.0003$ )
Loss modulus ( $G''$ )	0.49 ( $p = 0.0004$ )	0.10 ( $p = 0.49$ )	0.20 ( $p = 0.18$ )	0.35 ( $p = 0.0165$ )
Shear modulus ( $G^*$ )	0.63 ( $p < 0.0001$ )	0.24 ( $p = 0.11$ )	0.31 ( $p = 0.0328$ )	0.44 ( $p = 0.0019$ )
Damping ratio ( $\zeta$ )	-0.19 ( $p = 0.21$ )	-0.24 ( $p = 0.11$ )	-0.17 ( $p = 0.26$ )	-0.08 ( $p = 0.58$ )
Frequency dispersion coefficient	-0.50 ( $p = 0.0004$ )	-0.63 ( $p < 0.0001$ )	-0.50 ( $p = 0.0004$ )	-0.50 ( $p = 0.0003$ )

**Table 2.** Spearman correlations ( $r$ ) between histological features, biological data and biomechanical parameters. ALT alanine aminotransferase, AST aspartate aminotransferase.

Parameter	Explaining factor	$p$ value for the variable	$r_{\text{partial}}$	F ratio ( $p$ value) for the model
Storage modulus ( $G'$ )	Fibrosis	$< 0.0001$	0.68	33.5 ( $p < 0.0001$ )
Loss modulus ( $G''$ )	Fibrosis	$< 0.0001$	0.54	15.9 ( $p = 0.0003$ )
Shear modulus ( $G^*$ )	Fibrosis	$< 0.0001$	0.66	29.5 ( $p < 0.00001$ )
Damping ratio ( $\zeta$ )	None	n.a	n.a	n.a
Frequency dispersion coefficient	Activity	$< 0.001$	-0.60	21.8 ( $p < 0.0001$ )

**Table 3.** Multivariate analysis of the potential influence of the histological features (activity, fibrosis) and biological data (alanine aminotransferase, aspartate aminotransferase) on the biomechanical parameters. n.a. not assessed.



**Figure 5.** Receiver operating characteristics curves of storage modulus at 56 Hz (triangles) and multifrequency dispersion coefficient (circles) for substantial necro-inflammation  $\geq A2$  (A) and substantial fibrosis  $\geq F2$  (B). Multifrequency dispersion coefficient has significantly larger AUC than storage modulus for diagnosing necro-inflammation  $\geq A2$  (AUC of 0.84 vs. 0.65,  $p = 0.03$ ), whereas storage modulus has larger AUC than multifrequency dispersion coefficient for diagnosing fibrosis  $\geq F2$  (AUC of 0.91 vs. 0.79,  $p = 0.18$ ).

	A $\geq 1$		A $\geq 2$		A = 3	
	AUC (95% C.I.)	p value	AUC (95% C.I.)	p value	AUC (95% C.I.)	p value
G'	0.73 [0.58–0.85]	0.0064	0.65 [0.50–0.79]	0.13	0.83 [0.69–0.92]	<0.0001
G''	0.56 [0.41–0.71]	0.53	0.54 [0.39–0.68]	0.71	0.73 [0.58–0.85]	0.1027
G*	0.66 [0.50–0.79]	0.07	0.60 [0.45–0.74]	0.31	0.78 [0.64–0.89]	0.0061
$\zeta$	0.65 [0.50–0.79]	0.14	0.62 [0.47–0.76]	0.17	0.59 [0.44–0.73]	0.64
$\gamma$	0.86 [0.73–0.95]	<0.0001	0.84 [0.71–0.93]	<0.0001	0.88 [0.75–0.96]	<0.0001
ALT	0.80 [0.64–0.96]	0.0002	0.75 [0.57–0.92]	0.0051	0.74 [0.67–0.80]	<0.0001
AST	0.80 [0.73–0.85]	<0.0001	0.76 [0.69–0.82]	<0.0001	0.80 [0.74–0.85]	<0.0001
	F $\geq 2$		F $\geq 3$		F = 4	
	AUC (95% C.I.)	p value	AUC (95% C.I.)	p value	AUC (95% C.I.)	p value
G'	0.91 [0.79–0.98]	<0.0001	0.81 [0.67–0.91]	0.0001	0.97 [0.88–1.00]	<0.0001
G''	0.79 [0.64–0.89]	<0.0001	0.80 [0.65–0.90]	<0.0001	0.93 [0.81–0.98]	<0.0001
G*	0.89 [0.77–0.96]	<0.0001	0.81 [0.67–0.91]	0.0001	0.97 [0.88–1.00]	<0.0001
$\zeta$	0.59 [0.44–0.73]	0.28	0.58 [0.43–0.72]	0.37	0.60 [0.44–0.74]	0.44
$\gamma$	0.79 [0.65–0.90]	<0.0001	0.75 [0.60–0.87]	0.0013	0.57 [0.41–0.71]	0.65
ALT	0.85 [0.79–0.90]	<0.0001	0.82 [0.75–0.87]	<0.0001	0.78 [0.72–0.84]	<0.0001
AST	0.86 [0.80–0.91]	<0.0001	0.85 [0.79–0.90]	<0.0001	0.81 [0.75–0.87]	<0.0001

**Table 4.** Areas under the receiver operating characteristic curves of the biomechanical parameters and serum aminotransferase levels in necro-inflammatory activity grading and fibrosis staging. G', storage modulus; G'', loss modulus; |G\*|, shear modulus;  $\zeta$ , damping ratio;  $\gamma$ , frequency dispersion coefficient; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Monofrequency elasticity and stiffness measurements have been shown to be variably influenced by liver inflammatory activity<sup>4,9</sup>. Overall, it is accepted that early increase of stiffness and elasticity in chronic liver disease occurs before substantial matrix deposition<sup>9</sup>.

In chronic liver diseases, however, inflammation usually increases stiffness less than fibrosis does<sup>4,28</sup>. In contrast, increase in stiffness can be erroneously interpreted as elevation in fibrosis stage during acute inflammatory flares in patients with viral hepatitis<sup>29</sup>. Our results suggest that better discrimination between inflammation and fibrosis can be obtained with the multifrequency dispersion coefficient than with monofrequency stiffness measurements.

Viscosity related parameters, including loss modulus and damping ratio, have been reported to change at monofrequency MR elastography in NASH. The loss modulus and the damping ratio increased in animal models of NASH<sup>15,23</sup>, whereas the damping ratio decreased in patients with NASH relative to simple steatosis<sup>22</sup>. In our study of patients with chronic viral hepatitis, we did not observe these findings, and the damping ratio was not



relevant for diagnosing inflammation. Similar results about insensitivity of damping ratio to inflammation have been described in a study including 40 patients with hepatitis C viral infection and 5 patients with steatohepatitis related to human immune deficiency virus infection<sup>30</sup>. The variable reported influence of inflammation on the damping ratio might be explained by differences in cause and duration of chronic liver disease, and by differences in MR acquisition parameters.

In contrast to what we observed in our study, it has been reported that the damping ratio and the multifrequency wave dispersion coefficient can be related, especially if it is assumed that the tissue has a specific fractal hierarchy corresponding to a springpot model<sup>31</sup>. In that case, the dispersion coefficient has values between 0 (pure solid) and 1 (pure liquid). Here, we observed dispersion coefficients above one, in violation of the springpot model. However, this model might not be adequate for assessing chronic liver diseases<sup>21</sup>. Moreover, according to the unifying theory for shear and compression waves, the dispersion coefficient of the shear modulus may exceed one under high frequency assumption<sup>32</sup>. This would be consistent with the results of high multifrequency dispersion coefficient observed here and elsewhere<sup>18,27</sup>.

Assessing disease severity, i.e. liver fibrosis and inflammation, is clinically relevant in patients with chronic viral hepatitis. This is especially true in patients with chronic hepatitis B, whose treatment is based on the level of viremia, the severity of liver fibrosis and inflammation<sup>5,6,33</sup>. Liver fibrosis can be reliably evaluated with elastography, but development of non-invasive methods to assess liver inflammation are still needed. In patients with chronic hepatitis B, serum transaminase levels (especially AST) are widely used for this purpose. Studies have, however, shown limited correlations between serum ALT levels and histological activity<sup>34,35</sup>.

In patients with chronic hepatitis C, precise assessment of inflammation is less needed because universal treatment is currently recommended. However, assessment of disease severity with elastography is still recommended before treatment and this assessment can be biased when transaminase levels are elevated<sup>8</sup>. These considerations underscore the potential clinical relevance of multifrequency MR elastography to assess fibrosis and inflammation in patients with chronic viral hepatitis.

Our study had several limitations. First, the study was performed with a relatively small number of patients. However, differences in diagnostic performance of necro-inflammation were observed between multi- and monofrequency parameters. The limited number of patients prevented us from analyzing the imaging markers separately in hepatitis B and C patients and necessitated the pooling of the patients without or with substantial necro-inflammation (A0/A1 vs. A2/A3) and with no/mild fibrosis (F0/F1) versus moderate fibrosis (F2) and advanced fibrosis (F3/F4). However, similar pooling has been recommended in previous large clinical studies and may have clinical relevance<sup>33,36,37</sup>. Indeed, substantial necro-inflammation (A2/A3) is considered to be clinically significant<sup>33</sup> and advanced fibrosis (F3/F4) without cirrhotic decompensation is considered to correspond to clinically advanced compensated chronic liver disease<sup>37</sup>.

Second, only three mechanical frequencies were sampled. Using higher number of frequencies might be helpful in providing more exact estimates of the multifrequency dispersion coefficient. For instance, Asbach et al. used four frequencies in their study on liver fibrosis<sup>3</sup>, although with a lesser range (37.5 Hz, vs. 56 Hz in our study).

Third, the AUCs of the multifrequency dispersion coefficient were not statistically larger than those of the transaminase levels to assess necro-inflammatory severity. However, the multifrequency dispersion coefficient was the only coefficient with high AUC (> 0.8) for each activity grade. The lack of statistically significant difference may be related to the limited number of patients in our study. The diagnostic accuracy of the multifrequency dispersion coefficient relative to that of transaminase levels and other blood biomarkers of inflammation should be further assessed in large clinical trials.

Finally, only semi-quantitative histological scores were available for the reference examination. More advanced histological methods will be needed to explore the relationships between the biomechanical parameters and edema, angiogenesis and collagen structure.

In conclusion, our results suggest that, in contrast to liver fibrosis, necro-inflammatory activity may be better assessed with the multifrequency dispersion coefficient than with the monofrequency storage modulus. Hence three-dimensional multifrequency MR elastography, with its ability to generate both multi- and monofrequency parameters within a single examination could be a valuable tool for the non-invasive characterization of necro-inflammation and fibrosis in patients with chronic viral hepatitis.

## Methods

**Participants.** Between November 2010 and June 2012, 50 consecutive patients with chronic viral hepatitis B or C scheduled for liver biopsy in the department of hepatology of our tertiary university hospital were prospectively included. The protocol was approved by the local institutional review board ("Comité d'évaluation de l'éthique des projets de recherche biomédicale (CEERB) Paris Nord", IRB 00006477) of the Hôpitaux Universitaires Paris Nord Val De Seine perimeter of Assistance Publique—Hôpitaux de Paris, and written informed consents were obtained. All work presented herein was performed in accordance with relevant guidelines/regulations and the Declaration of Helsinki. In this work, we report previously unexploited data about multifrequency MR elastography dispersion of the shear modulus. These data were acquired in a subcohort of patients (examined between November 2010 and June 2012) extracted from a larger cohort of patients (examined between November 2010 and October 2012). The patients in the larger cohort were examined with conventional monofrequency MR elastography and MR diffusion imaging. The results in these patients have been published<sup>12</sup>. The subcohort presented here was additionally imaged with the proposed multifrequency MR elastography sequence.

**MR elastography acquisition.** MR elastography was performed in fasting patients with a 1.5 T MRI system (Intera, Philips Healthcare, Best, The Netherlands). T2-weighted MRI of the liver was performed for anatomical referencing. A gradient echo MR elastography sequence with fractional encoding was used (9 transverse



slices with 4 mm thickness, 4–5 mm in-plane resolution depending on patient size, 9.6 ms echo time, 112 ms repetition time, 25° flip angle, 8 phase offsets, 3 encoded directions and a reference with mechanical vibration but no motion encoding<sup>16</sup>. Synchronized mechanical vibrations of 28 Hz, 56 Hz and 84 Hz superimposed in one mechanical excitation were generated with an electromagnetic transducer (Philips Healthcare, Hamburg, Germany) placed against the right hypochondrium. The acquisition included four 19 s breath holds (supplementary material).

**MR data analysis.** For MR elastography reconstruction, the shear, storage and loss moduli, as well as the damping ratio<sup>38</sup> were calculated as described in the supplementary material. Only the 56 Hz frequency was considered for the single frequency analysis, as this frequency is closest to the reported frequency of 60 Hz often used in liver MR elastography<sup>4</sup>. The dimensionless multifrequency dispersion coefficient,  $\gamma$ , was calculated as described in the supplementary material.

The biomechanical parameters were measured by two physicists, PG and GP, with 8-year and 7-year expertise in abdominal MRI. The two physicists, who were blinded to the reference analyses, independently placed large regions of interest (ROIs) in the right liver, close to the transducer while avoiding large vessels and organ edges<sup>39</sup> on three consecutive MR elastography magnitude images. The ROI size was  $34.8 \pm 17.6 \text{ cm}^3$  and their location included the region of liver biopsy (segment 8). Datasets with  $< 3 \mu\text{m}$  of curl-filtered shear wave amplitude at any datasets were discarded.

**Histopathological and biological analyses.** Liver biopsies were performed within two months of the MR elastography examinations. Hepatic necro-inflammation and fibrosis were assessed on the histological samples according to the METAVIR classification with necro-inflammatory activity graded as A0 = no activity, A1 = mild activity, A2 = moderate activity, and A3 = severe activity, and with fibrosis staged as F0 = no fibrosis, F1 = portal fibrosis without septa, F2 = portal fibrosis with some septa, F3 = fibrosis with numerous septa, and F4 = cirrhosis<sup>40</sup>. The biopsies were taken in hepatic segment 8.

The histological analysis was performed by a medical doctor with 25-year expertise in gastrointestinal histopathology. All patients had at least a liver specimen with more than 10 portal tracts. The pathologist was blinded to the clinical, MR elastography and biochemistry results. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured at 37 °C within one week of the MR elastography acquisition.

**Statistical analysis.** The sample size was calculated to allow at least 90% power to detect at a 5% significance level, a significant difference between the area under the receiver operating characteristic curve (AUC) of the multifrequency dispersion coefficient and a null hypothesis value of 0.50, considering the AUC of the dispersion coefficient = 0.80 for  $A \geq 2$ , and the ratio of patients with  $A < 2/A \geq 2 = 1.5$ , similar to the ratio reported by Poynard et al.<sup>41</sup>. Under these conditions, a sample size of 35 patients was required.

The inter-rater reproducibility was analysed with intraclass correlation coefficients and Bland–Altman bias and reproducibility indexes as previously defined ( $1.96 \cdot \sqrt{2 \times \text{percentage standard deviation}}$ )<sup>42</sup>. Further analysis was carried out on the MR elastography measurements performed by the first reader.

Considering the small number of subjects in each METAVIR subgroup, the subjects were grouped in two activity classes, i.e. patients without (A0/A1) and with (A2/A3) substantial activity. For fibrosis severity, the participants were grouped in three classes with no/mild fibrosis (F0/F1), moderate fibrosis (F2), and severe fibrosis (F3/F4). Mann–Whitney and Kruskal–Wallis tests were respectively used to assess the differences in mechanical parameters between the inflammation and fibrosis classes.

The associations between necro-inflammatory activity, fibrosis, aminotransferase levels and viscoelastic parameters were assessed with Spearman rank correlation coefficients. Multivariate analysis was carried out with stepwise least squares multiple regression to investigate the influence of inflammation, fibrosis and aminotransferase levels on each biomechanical parameter. Parameters yielding  $p$  values greater than 0.1 were not retained. The partial regression coefficients and their associated  $p$  values were reported for the variables which were retained in the model.

The diagnostic performance of the viscoelastic parameters and aminotransferases serum levels was assessed with areas under the receiver operating characteristic curves (AUCs) and compared with the DeLong test. High diagnostic accuracy was considered for  $\text{AUC} > 0.8$ <sup>43</sup>. Sensitivity, specificity, positive and negative predictive values were calculated for the best viscoelastic parameters (storage modulus and multifrequency dispersion coefficient) using thresholds determined with Youden indexes to distinguish between different histopathological scores.

The results are expressed as mean  $\pm$  standard deviation or median and 95% confidence interval. Significance was considered for  $p \leq 0.05$ . The analyses were performed with Medcalc version 18.11.6\_64 (Medcalc Software, Ostend, Belgium).

## Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 22 April 2021; Accepted: 14 September 2021

Published online: 29 September 2021

## References

1. Castera, L. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* **128**, 343–350 (2005).

2. Huwart, L. *et al.* Magnetic resonance elastography for the noninvasive staging of liver fibrosis. *Gastroenterology* **135**, 32–40. <https://doi.org/10.1053/j.gastro.2008.03.076> (2008).
3. Asbach, P. *et al.* Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. *Radiology* **257**, 80–86. <https://doi.org/10.1148/radiol.10092489> (2010).
4. Shi, Y. *et al.* MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: Does histologic necroinflammation influence the measurement of hepatic stiffness?. *Radiology* **273**, 88–98. <https://doi.org/10.1148/radiol.14132592> (2014).
5. European Association for the Study of the Liver. Electronic address, e. e. e. & European Association for the Study of the, L. EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. *J. Hepatol.* **67**(370–398), 2017. <https://doi.org/10.1016/j.jhep.2017.03.021> (2017).
6. Terrault, N. A. *et al.* Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* **67**, 1560–1599. <https://doi.org/10.1002/hep.29800> (2018).
7. Panel, A.-I. H. G. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. *Clin Infect Dis* **67**, 1477–1492. <https://doi.org/10.1093/cid/ciy585> (2018).
8. European Association for the Study of the Liver. Electronic address, e. e. e., Clinical Practice Guidelines Panel, C., representative, E. G. B. & Panel, m. EASL recommendations on treatment of hepatitis C: Final update of the series(). *J Hepatol* **73**, 1170–1218, <https://doi.org/10.1016/j.jhep.2020.08.018> (2020).
9. Salameh, N. *et al.* Early detection of steatohepatitis in fatty rat liver by using MR elastography. *Radiology* **253**, 90–97. <https://doi.org/10.1148/radiol.2523081817> (2009).
10. Chen, J. *et al.* Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. *Radiology* **259**, 749–756. <https://doi.org/10.1148/radiol.11101942> (2011).
11. Reiter, R. *et al.* Wideband MRE and static mechanical indentation of human liver specimen: Sensitivity of viscoelastic constants to the alteration of tissue structure in hepatic fibrosis. *J. Biomech.* **47**, 1665–1674. <https://doi.org/10.1016/j.jbiomech.2014.02.034> (2014).
12. Leita, H. S. *et al.* Hepatic fibrosis, inflammation, and steatosis: Influence on the MR viscoelastic and diffusion parameters in patients with chronic liver disease. *Radiology* **283**, 98–107. <https://doi.org/10.1148/radiol.2016151570> (2017).
13. Garteiser, P., Doblas, S. & Van Beers, B. E. Magnetic resonance elastography of liver and spleen: Methods and applications. *NMR Biomed.* **31**, e3891. <https://doi.org/10.1002/nbm.3891> (2018).
14. Garteiser, P. *et al.* MR elastography of liver tumours: Value of viscoelastic properties for tumour characterisation. *Eur. Radiol.* **22**, 2169–2177. <https://doi.org/10.1007/s00330-012-2474-6> (2012).
15. Yin, M. *et al.* Distinguishing between Hepatic Inflammation and Fibrosis with MR Elastography. *Radiology* **284**, 694–705. <https://doi.org/10.1148/radiol.2017160622> (2017).
16. Garteiser, P. *et al.* Rapid acquisition of multifrequency, multislice and multidirectional MR elastography data with a fractionally encoded gradient echo sequence. *NMR Biomed.* **26**, 1326–1335. <https://doi.org/10.1002/nbm.2958> (2013).
17. Klatt, D., Hamhaber, U., Asbach, P., Braun, J. & Sack, I. Noninvasive assessment of the rheological behavior of human organs using multifrequency MR elastography: A study of brain and liver viscoelasticity. *Phys. Med. Biol.* **52**, 7281–7294. <https://doi.org/10.1088/0031-9155/52/24/006> (2007).
18. Sinkus, R. *et al.* MR elastography of breast lesions: Understanding the solid/liquid duality can improve the specificity of contrast-enhanced MR mammography. *Magn. Reson. Med.* **58**, 1135–1144. <https://doi.org/10.1002/mrm.21404> (2007).
19. Posnansky, O. *et al.* Fractal network dimension and viscoelastic powerlaw behavior: I: A modeling approach based on a coarse-graining procedure combined with shear oscillatory rheometry. *Phys. Med. Biol.* **57**, 4023–4040. <https://doi.org/10.1088/0031-9155/57/12/4023> (2012).
20. Kiss, M. Z., Varghese, T. & Hall, T. J. Viscoelastic characterization of in vitro canine tissue. *Phys. Med. Biol.* **49**, 4207–4218. <https://doi.org/10.1088/0031-9155/49/18/002> (2004).
21. Sack, I., Jöhrens, K., Würfel, J. & Braun, J. Structure-sensitive elastography: On the viscoelastic powerlaw behavior of in vivo human tissue in health and disease. *Soft Matter* **9**, 5672–5680. <https://doi.org/10.1039/C3SM50552A> (2013).
22. Allen, A. M. *et al.* The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery. *Hepatology* **71**, 510–521. <https://doi.org/10.1002/hep.30483> (2020).
23. Yin, Z. *et al.* Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography. *Eur. Radiol.* <https://doi.org/10.1007/s00330-019-06076-0> (2019).
24. Streitberger, K. J. *et al.* Brain viscoelasticity alteration in chronic-progressive multiple sclerosis. *PLoS ONE* **7**, e29888. <https://doi.org/10.1371/journal.pone.0029888> (2012).
25. Rebours, V. *et al.* Obesity-induced pancreatopathy in rats is reversible after bariatric surgery. *Sci. Rep.* **8**, 16295. <https://doi.org/10.1038/s41598-018-34515-3> (2018).
26. Ronot, M. *et al.* Viscoelastic parameters for quantifying liver fibrosis: Three-dimensional multifrequency MR elastography study on thin liver rat slices. *PLoS ONE* **9**, e94679 (2014).
27. Testu, J. *et al.* Viscoelastic power law parameters of in vivo human brain estimated by MR elastography. *J. Mech. Behav. Biomed. Mater.* **74**, 333–341. <https://doi.org/10.1016/j.jmbbm.2017.06.027> (2017).
28. Imajo, K. *et al.* Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. *Gastroenterology* **150**, 626–637. <https://doi.org/10.1053/j.gastro.2015.11.048> (2016).
29. Coco, B. *et al.* Transient elastography: A new surrogate marker of liver fibrosis influenced by major changes of transaminases. *J. Viral. Hepat.* **14**, 360–369. <https://doi.org/10.1111/j.1365-2893.2006.00811.x> (2007).
30. Sinkus, R. *et al.* Rheological determinants for simultaneous staging of hepatic fibrosis and inflammation in patients with chronic liver disease. *NMR Biomed.* **31**, e3956. <https://doi.org/10.1002/nbm.3956> (2018).
31. Schiessel, H. & Blumen, A. Mesoscopic pictures of the sol-gel transition: Ladder models and fractal networks. *Macromolecules* **28**, 4013–4019. <https://doi.org/10.1021/ma00115a038> (1995).
32. Holm, S. & Sinkus, R. A unifying fractional wave equation for compressional and shear waves. *J. Acoust. Soc. Am.* **127**, 542–559. <https://doi.org/10.1121/1.3268508> (2010).
33. Sonneveld, M. J. *et al.* Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. *Aliment Pharmacol. Ther.* **52**, 1399–1406. <https://doi.org/10.1111/apt.16067> (2020).
34. Wang, H. *et al.* Histologic disease in chinese chronic hepatitis B patients with low viral loads and persistently normal alanine aminotransferase levels. *J. Clin. Gastroenterol.* **50**, 790–796. <https://doi.org/10.1097/MCG.0000000000000544> (2016).
35. Li, Q., Zhou, Y., Huang, C., Li, W. & Chen, L. A novel diagnostic algorithm to predict significant liver inflammation in chronic hepatitis B virus infection patients with detectable HBV DNA and persistently normal alanine transaminase. *Sci. Rep.* **8**, 15449. <https://doi.org/10.1038/s41598-018-33412-z> (2018).
36. Paisant, A. *et al.* Reliability criteria of two-dimensional shear wave elastography: Analysis of 4277 measurements in 788 patients. *Clin. Gastroenterol. Hepatol.* <https://doi.org/10.1016/j.cgh.2020.12.013> (2020).
37. de Franchis, R. & Baveno, V. I. F. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J. Hepatol.* **63**, 743–752. <https://doi.org/10.1016/j.jhep.2015.05.022> (2015).

38. Sinkus, R. *et al.* Imaging anisotropic and viscous properties of breast tissue by magnetic resonance-elastography. *Magn. Reson. Med.* **53**, 372–387. <https://doi.org/10.1002/mrm.20355> (2005).
39. Bohte, A. E. *et al.* MR elastography of the liver: Defining thresholds for detecting viscoelastic changes. *Radiology* **269**, 768–776. <https://doi.org/10.1148/radiol.13122669> (2013).
40. Bedossa, P. & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* **24**, 289–293. <https://doi.org/10.1002/hep.510240201> (1996).
41. Poynard, T. *et al.* ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an over-view using Obuchowski measure. *Gastroenterol. Clin. Biol.* **34**, 388–396. <https://doi.org/10.1016/j.gcb.2010.05.001> (2010).
42. Serai, S. D. *et al.* Repeatability of MR elastography of liver: A meta-analysis. *Radiology* **285**, 92–100. <https://doi.org/10.1148/radiol.2017161398> (2017).
43. Mandrekar, J. N. Receiver operating characteristic curve in diagnostic test assessment. *J. Thorac. Oncol.* **5**, 1315–1316. <https://doi.org/10.1097/JTO.0b013e3181ec173d> (2010).

## Acknowledgements

The authors thank Valérie Paradis for performing the histological analysis. The work was carried out in a laboratory part of the France Life Imaging network (ANR-11-INBS-0006).

## Author contributions

P.G.: work conception and design, data acquisition, data analysis, data interpretation, drafting of the manuscript, revision of the manuscript, creation of software used in the work. G.P.: data analysis, drafting of the manuscript, revision of the manuscript, creation of software used in the work. G.D.A.: work conception and design, revision of the manuscript. H.L.: work conception and design, revision of the manuscript. V.V.: work conception and design, revision of the manuscript. R.S.: work design, data acquisition, data analysis, data interpretation, revision of the manuscript, creation of software used in the work. B.V.B.: work conception and design, data interpretation, drafting and revision of the manuscript. All authors have approved the submitted version and agree to be accountable for their contribution and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-98726-x>.

**Correspondence** and requests for materials should be addressed to P.G.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021